CURLIM will be attending BIO-Europe in Vienna

We’re excited to announce that CURLIM will be attending BIO-Europe in Vienna — November 3–5, 2025!

Following our recent Orphan Drug Designation (EU) and our recognition by the French government for innovative research  (I-Lab award-winning project), we are proud to present CLM001 at BIO-Europe : our breakthrough nanodrug developed for peripheral neuropathies such as Charcot-Marie-Tooth disease (CMT).

 CLM001 targets the root mechanisms of the disease, opening new therapeutic perspectives for patients.

Driven by cutting-edge nanomedical research, we’re deeply committed to advancing innovation in neurodegenerative and rare diseases.

We are open to connecting with partners who share our vision for transformative healthcare.

If you’ll be attending BIO-Europe, let’s connect!